For the accelerated approval crowd: "The guidance cautions that many serious diseases with unmet need have available biomarkers lacking the necessary evidence to support a conclusion on reasonably likely to predict clinical benefit."
https://insights.citeline.com/pink-sheet/pathways-and-standards/review-pathways/accelerated-approval-us-fda-explains-reasonably-likely-determination-criteria-YRA3ICLQ3FALDO23KK3HH27SUY/
https://insights.citeline.com/pink-sheet/pathways-and-standards/review-pathways/accelerated-approval-us-fda-explains-reasonably-likely-determination-criteria-YRA3ICLQ3FALDO23KK3HH27SUY/
Comments